Ybrain launches at-home depression electroceutical MINDD STIM+ Pro

Mental health electroceutical platform company Ybrain said Monday it has launched MINDD STIM+ Pro, an upgraded version of what it calls Korea’s first at-home electroceutical for depression.

MINDD STIM+ Pro is billed as a premium solution designed to improve treatment outcomes and access for patients while also boosting hospital profitability.

The new product is a non-reimbursed electroceutical that has received approval from the Ministry of Food and Drug Safety. Treatment consists of a 30-minute session once a day for six weeks.

In a pivotal clinical trial conducted at six medical institutions in Korea, the remission rate for major depressive symptoms reached 62.8 percent, while scores on the Korean version of the Beck Depression Inventory-II (K-BDI-II) improved by 47.74 percent, suggesting strong efficacy even though treatment was delivered in a home-based setting, the company said.

MINDD STIM+ Pro consists of a 15-inch touchscreen kiosk, six standard electroceutical modules and a set of personal-use consumables.

After clinicians enter a prescription into the kiosk, patients take the assigned module home and continue treatment there. Compared with the existing MINDD STIM product, the number of standard modules has been tripled to six and consumables increased tenfold, allowing hospitals to treat more patients at once, Ybrain said.

The system can link up to six modules simultaneously so multiple patients can be managed in parallel, while accumulated clinical data and adherence monitoring are used to support more personalized care. 

It is aimed in particular at patients who struggle to visit hospitals frequently, enabling them to continue therapy at home through out-of-hospital prescriptions.

“The reason we expanded the number of modules in this new product is that analysis of prescription data from the existing MINDD STIM showed that as the number of modules increases, the proportion of home-based treatment via out-of-hospital prescriptions also rises,” CEO Lee Ki-won said. “MINDD STIM+ Pro will act as a key solution that accelerates the digital transformation of psychiatric hospitals, builds a patient-centered treatment environment and maximizes operational efficiency.”

Ybrain’s MINDD STIM depression electroceutical is currently supplied to 174 hospitals in Korea, with cumulative prescriptions exceeding 220,000, according to the company.